Nie Yanli, Zhao Wei, Lu Li, Zhou Fuxiang
Department of Gastrointestinal Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430079, Hubei, China.
PLA Rocket Force Characteristic Medical Center Beijing 100088, China.
Am J Cancer Res. 2023 Jul 15;13(7):3169-3184. eCollection 2023.
Gastric cancer is an extremely common digestive tract tumor. The promotion and application of standardized therapy, treatment scheme optimization, and development of new targeted drugs and immunotherapies have improved gastric cancer survival somewhat. However, gastric cancer prognosis generally remains non-optimistic. Immune checkpoint inhibitors (ICI) have gradually become a new choice for gastric cancer treatment and can prolong the survival of some patients. Among them, high-microsatellite instability, Epstein-Barr virus-positive status, or high-tumor mutational burden patients with gastric cancer may be the potential population to benefit from immunotherapy. Nevertheless, there remains a lack of unified and effective predictive markers. Accordingly, this review mainly focused on the possible predictive biomarkers of anti-PD-1/PD-L1 in gastric cancer treatment. Furthermore, the application of anti-PD-1/PD-L1 therapy-related clinical trials on gastric cancer is discussed. The current findings suggest that immunotherapy is a promising application in gastric cancer treatment. Therefore, combining immunotherapy and other therapies may be the trend in the future. Nevertheless, exploring biomarkers to predict ICI response remains a major challenge.
胃癌是一种极为常见的消化道肿瘤。标准化治疗的推广与应用、治疗方案的优化以及新型靶向药物和免疫疗法的研发在一定程度上提高了胃癌患者的生存率。然而，胃癌的预后总体上仍然不容乐观。免疫检查点抑制剂（ICI）已逐渐成为胃癌治疗的新选择，并且能够延长部分患者的生存期。其中，微卫星高度不稳定、爱泼斯坦-巴尔病毒阳性或肿瘤突变负荷高的胃癌患者可能是从免疫治疗中获益的潜在人群。尽管如此，仍然缺乏统一且有效的预测标志物。因此，本综述主要聚焦于胃癌治疗中抗程序性死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）治疗的可能预测生物标志物。此外，还讨论了抗PD-1/PD-L1疗法在胃癌相关临床试验中的应用。目前的研究结果表明，免疫疗法在胃癌治疗中具有广阔的应用前景。因此，将免疫疗法与其他疗法相结合可能是未来的发展趋势。尽管如此，探索预测ICI反应的生物标志物仍然是一项重大挑战。
